Repurposing immunosuppressants for antileukemia therapy.

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Drug repurposing is an efficient strategy for developing new therapeutics.
• Acute myeloid leukemia with MLL rearrangements is an aggressive blood cancer.
• Inosine monophosphate dehydrogenase (IMPDH) inhibitors are known immunosuppressants.

Purpose of the Study:

• To investigate the therapeutic potential of IMPDH inhibitors for acute myeloid leukemia (AML).
• To elucidate the mechanisms underlying the antileukemia effects of IMPDH inhibitors.

Main Methods:

• Evaluation of IMPDH inhibitors in vitro and in vivo models of AML.
• Analysis of Toll-like receptor (TLR) signaling pathway activation.
• Assessment of Vcam1 expression levels.

Main Results:

• IMPDH inhibitors demonstrated a potent therapeutic effect against AML with MLL rearrangements.
• The antileukemia activity was partly mediated by the overactivation of TLR signaling.
• Upregulation of Vcam1 was observed as a key mechanism.

Conclusions:

• IMPDH inhibitors show robust efficacy in preclinical models of AML.
• Targeting IMPDH offers a rational approach for repurposing these drugs in antileukemia therapy.
• The findings provide a basis for clinical trials of IMPDH inhibitors in AML patients.